Earlier this week, India, at the request of President Donald Trump, authorized the export of 35.82 lakh hydroxychloroquine tablets to the United States as well as nine metric tonnes of active pharmaceutical ingredient or API necessary for the manufacture of the drug.
“Support our partners in the fight against COVID-19. A batch of hydroxychloroquine from India arrived at Newark Airport today, “tweeted Ambassador of India to the United States, Taranjit Singh Sandhu.
In a phone call last week, Trump asked Prime Minister Narendra Modi to lift the suspension of the US order for the antimalarial drug, of which India is the largest producer. India, which makes 70% of the world’s supply of hydroxychloroquine, lifted the ban on April 7.
Hydroxychloroquine has been identified by the United States Food and Drug Administration as a possible treatment for COVID-19 and has been tested on more than 1,500 patients with coronavirus in New York.
Anticipating that it will work, given the initial positive results, Trump has purchased more than 29 million doses of hydroxychloroquine for the potential treatment of COVID-19 patients.
The arrival of the shipment was welcomed by the Americans. “The United States will never forget this great humanitarian gesture from India. Under President Trump and Prime Minister Narendra Modi, the two largest democracies in the world have come together more than ever in the past, “said Al Mason, a New York-based real estate consultant. and a Trump supporter.
“A wonderful gesture from India to friends in need,” tweeted Dr. Sampat Shivangi. Describing this as a “wonderful gesture,” Steve Filipovic, who works in the construction industry, thanked the Indian ambassador.
Meanwhile, according to a new French study of 1,061 COVID-19 hospital patients, a 91.7% cure (viral excretion) was observed within 10 days of treatment with hydroxychloroquine with an antibiotic. He also reported a 96% cure rate after 15 days.
Earlier this week, the National Institute of Health announced that a clinical trial to assess the safety and efficacy of hydroxychloroquine for the treatment of adults hospitalized for coronavirus disease 2019 (COVID-19) started, the first participants are now registered in Tennessee.
Hydroxychloroquine is used to treat malaria and rheumatoid conditions such as arthritis. In various studies, the drug has demonstrated antiviral activity, an ability to modify the activity of the immune system and a safety profile established at appropriate doses, which leads to the hypothesis that it could also be useful in the treatment from COVID-19, Says NIH.
The drug is not without risks because even short-term use can cause heart arrhythmias, seizures, dermatological reactions and hypoglycemia, he added.
“Many American hospitals are currently using hydroxychloroquine as a first-line treatment for inpatients with COVID-19 despite extremely limited clinical data supporting its effectiveness,” said Wesley Self, emergency physician at Vanderbilt University Medical Center and investigator for the PETAL Clinical Trials Network at the head of the ORCHID Trial.
“Thus, data on hydroxychloroquine for the treatment of COVID-19 are urgently needed to inform clinical practice,” he added.
According to NIH, participants will be randomly assigned to receive hydroxychloroquine 400 mg twice daily for two doses (day one), then 200 mg twice daily for the next eight doses (days two to five) or one placebo twice daily for five days.
The COVID-19 cases were first identified in December 2019 in Wuhan, Hubei Province, China.
On Saturday, more than 16 lakh people around the world tested positive and more than one lakh died. The United States has become the hotspot with 20,000 deaths and 5.3 lakh cases